<SEC-DOCUMENT>0001087294-25-000012.txt : 20251021
<SEC-HEADER>0001087294-25-000012.hdr.sgml : 20251021
<ACCEPTANCE-DATETIME>20251021092532
ACCESSION NUMBER:		0001087294-25-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251021
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20251021
DATE AS OF CHANGE:		20251021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				621765329
		STATE OF INCORPORATION:			TN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		251405525

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST END AVENUE
		STREET 2:		SUITE 1300
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		1600 WEST END AVENUE
		STREET 2:		SUITE 1300
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20251021.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90383531-28f9-47e0-956d-e581ef3f43bf,g:88b6385a-3e21-48e9-aaba-43a76a9e574d,d:dfa6b5efef9d4508964ca5c11944c283-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20251021</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20251021.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-21</xbrli:startDate><xbrli:endDate>2025-10-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idfa6b5efef9d4508964ca5c11944c283_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">October 21, 2025 (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 21, 2025</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1600 West End Avenue, Suite 1300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idfa6b5efef9d4508964ca5c11944c283_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2025, Cumberland Pharmaceuticals Inc. (&#8220;Cumberland&#8221;) announced strategic arrangements with RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the release is furnished as </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cumberlandtaliciaannouncem.htm">Exhibit 99.1</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:22.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cumberlandtaliciaannouncem.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cumberlandtaliciaannouncem.htm">Press release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cumberlandtaliciaannouncem.htm">October 21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cumberlandtaliciaannouncem.htm">, 2025</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="idfa6b5efef9d4508964ca5c11944c283_7"></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dated: October 21, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cumberlandtaliciaannouncem.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2ce0d5cee0e8454cbc57251544bbcb15_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:383px"></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS ANNOUNCES THE ADDITION OF AN </font></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Cumberland to expand its gastroenterology offerings </font></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">with the market-leading Helicobacter pylori therapy </font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">NASHVILLE, Tenn., (Oct. 20, 2025) &#8211;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (Nasdaq&#58; CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RedHill Biopharma Ltd. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(Nasdaq&#58; RDHL), a specialty biopharmaceutical company, to jointly commercialize </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Talicia</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">FDA-approved oral capsule is indicated for the treatment of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Helicobacter pylori</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> infection in adults, a bacterial infection and leading risk factor for gastric cancer. </font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Under the terms of the agreement, Cumberland and RedHill will form a new, jointly owned company. RedHill will contribute all its Talicia assets to the new company, including the product&#8217;s growing international licenses with associated revenues. Cumberland will provide $4 million in investment capital. Cumberland will assume responsibility for the product&#8217;s distribution and record the product sales. Talicia net revenues were $8 million in 2024.  The two companies will equally share in those net revenues and collaborate on all operational aspects, including sales, marketing, manufacturing, regulatory and supply chain functions. Through this co-commercialization agreement, Cumberland will leverage its established national field sales force to lead promotional efforts for Talicia and expand its reach among office-based healthcare providers.</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Talicia features an outstanding clinical profile and represents an excellent strategic match for our organization,&#8221; said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. &#8220;It provides us with an immediate growth opportunity, as we will build on the excellent foundation RedHill has created and bring this critical therapy to many more patients.&#8221;</font></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin. It was FDA approved based on two large Phase 3 studies demonstrating excellent safety and efficacy results. The product features include three key advantages&#58; 1) high eradication rates at &#62;90%,  2) simplicity of an all-in-one capsule and 3) low resistance. </font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As a result of these attributes, Talicia is now listed as a </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">first line option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> in the newly updated </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">American College of Gastroenterology</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> guidelines for the treatment of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> infections.</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;These arrangements represent an excellent opportunity for Cumberland, a highly capable and driven partner with a strong gastroenterology market presence, to add a market-leading approved product to its portfolio,&#8221; said Rick Scruggs, Chief Commercial Officer of RedHill Inc. We believe Cumberland can help drive prescriptions and deliver revenue growth, further strengthening Talicia&#8217;s U.S. market leadership.&#8221; </font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The product is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.</font></div><div style="margin-bottom:6pt;margin-top:8pt"><font style="background-color:#ffffff;color:#111111;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">There is broad U.S. insurance coverage established for the product with includes 70% of American lives covered by commercial plans and 60% coverage by government plans.</font></div><div style="margin-bottom:6pt;margin-top:8pt"><font style="background-color:#ffffff;color:#111111;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Talicia is dispensed by retail pharmacies across the country. An agreement with CVS provides for stocking of the product at 1,700 of their pharmacies.</font></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For full prescribing information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.talicia.com&#47;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Talicia</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.85pt;vertical-align:baseline">&#174;</font></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Approved by the FDA for the treatment of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> infection in adults in November 2019, Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole). Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents extending patent protection through 2042 with additional patents and applications pending and granted in various territories worldwide. </font></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About RedHill Biopharma</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">RedHill&#160;Biopharma Ltd. (Nasdaq&#58;&#160;RDHL) is a specialty biopharmaceutical company primarily focused on&#160;U.S.&#160;development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology.&#160;RedHill&#160;promotes the FDA approved gastrointestinal drug&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Talicia</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;for the treatment of&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Helicobacter pylori (H. pylori)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;infection in adults</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">i</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;RedHill's&#160;key clinical late-stage development programs include&#58; (i)&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">opaganib (ABC294640)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, a first-in-class, orally administered&#160;sphingosine&#160;kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anticancer activity, targeting multiple indications with&#160;U.S. government and academic collaborations for development for radiation and chemical exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2&#47;3 program for hospitalized COVID-19, and a Phase 2 study in prostate cancer in combination with darolutamide&#59; (ii) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RHB-204</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, a next-generation optimized formulation of RHB-104, with a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">planned Phase 2 study for Crohn&#8217;s disease (based on RHB-104&#8217;s positive Phase 3 Crohn&#8217;s disease study results) and Phase 3-stage for pulmonary&#160;nontuberculous mycobacteria&#160;(NTM) disease&#59; (iii)&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RHB-107&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">upamostat</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">), an oral broad-acting, host-directed,&#160;serine&#160;protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases&#59; and (iv)&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RHB-102</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for&#160;IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR&#58; HYL) for worldwide development and commercialization outside North America.</font></div><div style="margin-bottom:18pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">More information about the Company is available at </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.redhillbio.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> &#47; </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">X.com&#47;RedHillBio</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Inc. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The Company&#8217;s portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:20.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Sancuso</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">granisetron</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;padding-right:20.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.                  </font></div><div style="margin-bottom:6pt;margin-top:8pt;padding-right:12.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The company also has Phase II clinical studies evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy, systemic sclerosis and idiopathic pulmonary fibrosis.</font></div><div style="margin-bottom:18pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, which can be found on the company&#8217;s website&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company&#8217;s intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221; &#8220;look forward&#8221; and other comparable terms or the negative thereof. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company&#8217;s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), as well as the company&#8217;s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Media Contact&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Shayla Simpson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emily Kent</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dalton Agency</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(615) 255-0068&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(540) 621-5448</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">i</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20251021.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90383531-28f9-47e0-956d-e581ef3f43bf,g:88b6385a-3e21-48e9-aaba-43a76a9e574d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20251021" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20251021">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20251021_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20251021_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20251021_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90383531-28f9-47e0-956d-e581ef3f43bf,g:88b6385a-3e21-48e9-aaba-43a76a9e574d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_ca2e01d1-c9b5-4507-a901-7ec746c7330f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_46bb7799-aceb-45bd-865b-30330c4fb8e1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_06eb9df2-302b-419b-9b9f-09434d8b0fb9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_070a4b68-abff-4ea7-a4fa-80434bff7e40_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9fe47110-0535-46a7-8542-e87b487821f0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7e534e53-281c-4eb0-847e-06b27b694476_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c2a23494-9dab-4755-9560-280a0b9834f2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_71981818-fa6d-45ad-81a1-d3b002ff3eeb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_33fb6748-36ff-41a9-abae-b11a9971b503_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6aced97b-c16b-48e3-a1a2-5715b78eb4d7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_eda14ce9-beea-4b33-837b-ae154ccac929_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f50b4274-4cf8-4e43-bf4b-b0c7355a5f4b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3c98ea73-131b-49a2-83b5-3b40e1cbc822_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6dc64477-0d8b-4e8e-96eb-50dca77d7951_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f58b95f1-c963-46a5-84eb-0cb1a23b8a31_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b9c008f1-18fd-4b43-b74a-bf16c1fc5c75_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bf3ed22d-951a-4c7c-9e5f-b09b7a85d80a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9a26e285-b799-41cb-8552-744471811916_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_51c4d408-303f-452b-a7b4-a6d64c0b9f06_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b29b535b-f9a4-4701-a3fc-2ea2ca8280b7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_70acfabf-46de-437a-94ec-3ebbf88c143b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_58a1bfdb-b609-4646-8642-4677e64f8ccc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a32a39fb-2ef3-4374-abd6-572ce2b1aae6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20251021_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90383531-28f9-47e0-956d-e581ef3f43bf,g:88b6385a-3e21-48e9-aaba-43a76a9e574d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20251021.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_edbaf460-479b-4f8a-b80a-0b188cd3a8bd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_DocumentType_edbaf460-479b-4f8a-b80a-0b188cd3a8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_de2ffbf4-4f97-4be6-9994-bedd8b68c54e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_DocumentPeriodEndDate_de2ffbf4-4f97-4be6-9994-bedd8b68c54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f8105762-3a66-47f0-b20c-27f424e6e1d0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityRegistrantName_f8105762-3a66-47f0-b20c-27f424e6e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5f6844d5-1fa7-4c5b-9e98-c29c17d8aecd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityCentralIndexKey_5f6844d5-1fa7-4c5b-9e98-c29c17d8aecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b923be85-998e-4e97-a590-220d931cfbd9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_AmendmentFlag_b923be85-998e-4e97-a590-220d931cfbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6f6453d5-2e1d-4104-9a19-69de51fc5fd5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6f6453d5-2e1d-4104-9a19-69de51fc5fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_66d18288-e92c-4cd5-adf3-2560e23af52e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityFileNumber_66d18288-e92c-4cd5-adf3-2560e23af52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cdfa44cb-d2c2-472a-854f-7ed8f55d55fc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityTaxIdentificationNumber_cdfa44cb-d2c2-472a-854f-7ed8f55d55fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ba5ffcc3-fb0e-4005-a37d-b76a9608d0cb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_CityAreaCode_ba5ffcc3-fb0e-4005-a37d-b76a9608d0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cbf49946-95fc-43c6-b6b6-0624c1f22a72" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_LocalPhoneNumber_cbf49946-95fc-43c6-b6b6-0624c1f22a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_c2e1693a-7a06-412b-bfb3-1982ddd71c3b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_WrittenCommunications_c2e1693a-7a06-412b-bfb3-1982ddd71c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3e3d8636-aa71-4358-ab0b-33d742e9b353" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_SolicitingMaterial_3e3d8636-aa71-4358-ab0b-33d742e9b353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_26b391df-b47d-436a-877f-e15c41af5565" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_PreCommencementTenderOffer_26b391df-b47d-436a-877f-e15c41af5565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_1552a8aa-d154-4d54-bb4b-bf5c0e4bc87b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_1552a8aa-d154-4d54-bb4b-bf5c0e4bc87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a1a7cb5e-d50a-4078-ae69-8087b104a909" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_Security12bTitle_a1a7cb5e-d50a-4078-ae69-8087b104a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dbe1388a-9e6a-43e3-ad0d-77e93d926a07" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_TradingSymbol_dbe1388a-9e6a-43e3-ad0d-77e93d926a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a3281ced-a047-4d1d-91ff-642397863282" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_SecurityExchangeName_a3281ced-a047-4d1d-91ff-642397863282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_832f6fa2-a4f3-414c-bf72-9eb1e3da180d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityEmergingGrowthCompany_832f6fa2-a4f3-414c-bf72-9eb1e3da180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ca08cb07-5282-4170-9f60-56579f190635" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityAddressAddressLine1_ca08cb07-5282-4170-9f60-56579f190635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_51fd2468-8d61-4449-8fdd-1ff304172db5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityAddressCityOrTown_51fd2468-8d61-4449-8fdd-1ff304172db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_58d92e78-eb7a-4666-b3c3-21d9da484da9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityAddressStateOrProvince_58d92e78-eb7a-4666-b3c3-21d9da484da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9b75e956-7105-4583-bd2a-5385a5a7dfa5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_574cbb60-33ae-40ed-a164-7a7ffdab329f" xlink:to="loc_dei_EntityAddressPostalZipCode_9b75e956-7105-4583-bd2a-5385a5a7dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !7 7\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_"BB@<__
M %N: "BN9\1^,/#OA2%9M<U.WLVD.V"W+![NZ?M';6J9FG<]A&AR<#/-?&7Q
MP_;0?X9Z==7&@^!KK4I8XW,,NLW:Z=&Q RDBV\:3W#+_ 'DF%NXXX'6NC#X3
M$8NI&E0IN4I-**>B>UVF_P _(B<XP3;>EKNV]O+L?<]_?V>F6-WJ.H7$5I96
M5O+=75S/(L4,$$"&26621B%1$C5F9B0 H)/&:\K^!7QAT'X\?#?2OB7X7:&7
M0=:OM;MM,N8)O/AN[?2-8O=)^U12A55X[A[)Y8RH*E&!#$8-?QN_\%'_ /@J
MI^U1\2/"WB/X?:3K]G\//"6J6]W9:G9^$(Y;74+^Q</');7.JRR/=)%+&QCF
M6!HED4X/!P/Z+O\ @B@[R?\ !,[]EV21F=Y/!MV[NY+%F;7-3)9F;YBS')8G
MDGKS7T^:\)8S)<DHYGC9057$XJ%&E2@W)0AR2G)R>SD[6TT7STX*.80KXV6&
MIQM&G3=1R=KN[22LO6^MK]M#]5****^0/2"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3[7Q[H :.!M<MHTL?$%L@8*9&9 (+LJO.UU4G&-V2*^)/3/ZA**\O\ A/\
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M%OQ9\6SJKZAXA\::KH\UQJ!GN6'G2VUE([6UM&S$*JM(<O(Y/]E?P/./@O\
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MTV[\5ZS!9Z=+_9.H:=*J6EQ%/.!*[H#/\J@Y-?KF_P#P21_X+$;&_P"-NOC
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MA^^'B74=+,C:6^N:[KFJ:_?6^G/.D4LMG8R:D+&&:1$:Y%L;CRXQ+L7\Y?\
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MN+H8G!TH)UL)#$*I"5WST5;6,NKBGJG?K;LC]W?^"@?_ "9/^T][_!CQZ/\
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M>&O"3".YLM&EW%XK[5&P8[K45 !2%0T%LXSN>10:_4!55%"*H55 55  "@<
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M'T^X^(G@S3=<U#2C_P 2S6%,]AK=@"<LEIK&GRVVHP1L?O1QW 1NZFJGPO\
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MWS131E9(V 9&4\UV%%-2FI*:G+G3OS)M2O9ZWO>_6X<JM9KW;:*WX;K1_?\
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M8'3+N=]9UG41)9&>.X,(BU*^NHD_>PQL'1%<;<;MI(KW>BB-6K&'LE4G[/\
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MO0+:+U:^ZW^84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Oct. 21, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 21,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue, Suite 1300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20251021.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20251021.htm">cpix-20251021.htm</File>
    <File>cpix-20251021.xsd</File>
    <File>cpix-20251021_lab.xml</File>
    <File>cpix-20251021_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20251021.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20251021",
   "dts": {
    "inline": {
     "local": [
      "cpix-20251021.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20251021.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20251021_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20251021_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20251021.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20251021.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001087294-25-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001087294-25-000012-xbrl.zip
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MZEJ#/XKR1W8GP/E,5&E1SB$\KI]V4MP\EMG5=04"%(3K9>O?EN\X(HR$!,.
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MEP,O@K:"C0;/+AN;W.Q<XX[,27&GRX]R495"55,4(T%EQ*"0:0JI%F:JHZF
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M@G4T<KQ9/$$25[A/)P</ ^VE?>?^Y.!_4$L#!!0    ( "]+55N2;KI$QA0
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MWN_9Z&YN5*Z@TK30W(J8*&G9)V]2">R9E$Z/B2G9)#$K_)WVNN'HQ%A++Z[
MO0?:*4)%'\,8UOY^?/!Q'2OF0!8V:G]>HN>HV9?1%58> VH'P@[XWV[XUN-_
M#T9FR[MB?6O@U#&Q=.9*2[@)B#/XATW?<,XY]Y(:@)X3+[O?$]5K\T4,[GQ#
M!#Z;V]<BAY1X07B!M^K.\-"0/F=L3_BA_PQ:3U%:K%U.FRQ,$:L ZY,J2$,
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M_P)02P$"% ,4    "  O2U5;/^V:OQ$/  !P:P  $0              @ $
M    8W!I>"TR,#(U,3 R,2YH=&U02P$"% ,4    "  O2U5;1T./]WP"  !F
M!P  $0              @ % #P  8W!I>"TR,#(U,3 R,2YX<V102P$"% ,4
M    "  O2U5;G4*BF# *  ",50  %0              @ 'K$0  8W!I>"TR
M,#(U,3 R,5]L86(N>&UL4$L! A0#%     @ +TM56QD0WZ>_!@  0S$  !4
M             ( !3AP  &-P:7@M,C R-3$P,C%?<')E+GAM;%!+ 0(4 Q0
M   ( "]+55N2;KI$QA0  *YT   >              "  4 C  !C=6UB97)L
M86YD=&%L:6-I86%N;F]U;F-E;2YH=&U02P4&      4 !0!0 0  0C@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>cpix-20251021_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20251021.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-10-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1600 West End Avenue, Suite 1300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
